People · Operator
Named in public records as an officer, director or promoter · active 2024–2026 · Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Scorpion Therapeutics, Inc. | — | Biotechnology | Series D+ | $297.4M | $1.4B | 2024 |
| Aktis Oncology, Inc. | — | Biotechnology | Series D+ | $175.0M | $1.8B | 2024 |
| Epikast Inc. | — | Other Health Care | Series A | $5.7M | $1.9M | 2026 |
Oleg Nodelman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Oleg Nodelman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jean-Francois Formela | 1 | 17 |
| Todd Foley | 1 | 12 |
| Shelley Chu | 1 | 10 |
| Gary Glick | 1 | 7 |
| Adam Friedman | 1 | 6 |
| Helen S. Kim | 1 | 6 |
| Arjun Goyal | 1 | 5 |
| Keith Flaherty | 1 | 5 |
| Otello Stampacchia | 1 | 4 |
| Stelios Papadopoulos | 1 | 4 |
| Matthew Roden | 1 | 3 |
| Jeffrey Albers | 1 | 3 |
| Brian Piper | 1 | 2 |
| Daphne Karydas | 1 | 2 |
| Evangelos Vergetis | 1 | 2 |
| Andrew Fedder | 1 | 2 |
| Andrew S. Levin | 1 | 2 |
| Saurabh Saha | 1 | 1 |
| Mark Chao | 1 | 1 |
| Jean-Francois Joseph Formela | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.